Evaluation of EB01 Cream for the Treatment of Chronic Allergic Contact Dermatitis

PHASE2CompletedINTERVENTIONAL
Enrollment

211

Participants

Timeline

Start Date

October 15, 2019

Primary Completion Date

September 21, 2022

Study Completion Date

January 17, 2023

Conditions
Allergic Contact Dermatitis
Interventions
DRUG

EB01 Cream Placebo

Vehicle Cream containing 0% EB w/w applied BID

DRUG

EB01 Cream 0.2%

EB01 Cream containing 0.2% EB01 w/w applied BID

DRUG

EB01 Cream 1.0%

EB01 Cream containing 1.0% EB01 w/w applied BID

DRUG

EB01 Cream 2.0%

EB01 Cream containing 2.0% EB01 w/w applied BID

Trial Locations (15)

10022

JUVA Skin & Laser Center, New York

20016

Foxhall Dermatology, Washington D.C.

26505

West Virginia Research Institute, Morgantown

27516

UNC Dermatology and Skin Cancer Center, Chapel Hill

33176

Miami Dade Medical Research Institute, LLC, Miami

33446

Gold Coast Dermatology, Delray Beach

40202

Forefront Dermatology, Louisville

43209

Bexly Dermatology, Bexley

44124

Apex Clinical Research Center, LLC, Mayfield Heights

46168

The Dermatology Centre of Indiana, Plainfield

48326

Oakland Hills Dermatology P.C., Auburn Hills

55432

Associated Skin Care Specialists, Fridley

70808

The Dermatology Clinic, Baton Rouge

90806

Ark Clinical Research, Long Beach

L3P 1X2

Lynderm Research Inc., Markham

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

JSS Medical Research Inc.

INDUSTRY

lead

Edesa Biotech Inc.

INDUSTRY